Abstracts tagged "Rheumatoid Factor"

Abstract Number: 0883 • ACR Convergence 2022
Serum Cholesterol Loading Capacity on Macrophages Is Dependent on Oxidized Low-density Lipoprotein and Regulated by Seropositivity and C-reactive Protein in Patients with Rheumatoid Arthritis
George A Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², elizabeth Hernandez³, Maria Pia Adorni², Francesca Zimetti², Matthew Budoff⁴ and Nicoletta Ronda⁵, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Parma, Italy, ³The Lundquist Institute, Torrance, CA, ⁴Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA, ⁵University of Parma, Parma
Background/Purpose: Excessive cholesterol accumulation in macrophages underlies foam cell formation, initiation and progression of atherosclerosis. Low-density lipoprotein (LDL) oxidation and unregulated uptake by macrophages are…
Abstract Number: 0891 • ACR Convergence 2022
Rheumatoid Arthritis and the Rheumatic Disease Comorbidity Index (RDCI): Its Impact on Disease Activity
Sultana Abdulaziz¹, Suzan Attar², Renad Ahmed², Hamza Fida², Omar Bokhary², Anas Alyazidi² and Abdulelah Abumohssin², ¹King Fahad Hospital, Jeddah, Saudi Arabia, ²King Abdulaziz University, Jeddah, Saudi Arabia
Background/Purpose: Comorbid conditions in the setting of rheumatoid arthritis (RA) play an important role in predicting disease activity and functional impairment (1). Application of a…
Abstract Number: 0906 • ACR Convergence 2022
Patients with Seronegative Rheumatoid Arthritis Have a Different Ultrasound-assessed Joint Disease Phenotype Than Seropositive Patients
Natalia Carbonell-Bobadilla¹, Carina Soto-Fajardo², Luis M Amezcua-Guerra³, Ana Beatriz Batres Marroquin⁴, Ana Cristina Medina⁵, Tania Vargas³, Adrián Hernández-Diazcouder³, Valentín Jiménez-Rojas³, Carlos Pineda⁵ and Luis H Silveira⁶, ¹National Institute of Cardiology Ignacio Chávez, Ciudad de México, Mexico, ²Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra", Ciudad de México, Mexico, ³Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ⁴Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Ciudad de México, Mexico, ⁵Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, ⁶Instituto Nacional de Cardiología, Ciudad de México, Mexico
Background/Purpose: Seronegative rheumatoid arthritis (SNRA) tends to be less severe in its presentation and evolution than seropositive rheumatoid arthritis(SPRA), but controversy exists because there have…
Abstract Number: 0910 • ACR Convergence 2022
Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies
Albert Pérez-Isidro¹, Raul Castellanos-Moreira¹, Juan Camilo Sarmiento-Monroy², Noemi de Moner¹, Maresa Grundhuber³, Odette Vinas¹, Raimon Sanmarti² and Estibaliz Ruiz-Ortiz¹, ¹Hospital Clinic of Barcelona, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Thermo Fisher Scientific, Freiburg, Germany
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation. RA-associated interstitial lung disease (ILD) is the most frequent and severe extra-articular…
Abstract Number: 0269 • ACR Convergence 2021
Autoantibodies and the Risk of Incident Cardiovascular Disease in US Veterans with Rheumatoid Arthritis
Tate Johnson¹, Michael Duryee², Carlos Hunter², Punyasha Roul², Yangyuna Yang², Jeremy Sokolove³, William Robinson⁴, Joshua Baker⁵, Geoffrey Thiele², Ted Mikuls² and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Stanford University School of Medicine, Berwyn, PA, ⁴Stanford University, Stanford, CA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Autoantibodies are hypothesized as one of the RA specific factors contributing to a heightened risk of cardiovascular disease (CVD) in this population. However, prior…
Abstract Number: 0273 • ACR Convergence 2021
Abnormalities in Left Ventricular Geometry Influenced by Higher Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Titers in Rheumatoid Arthritis Patients
Natalia Guajardo-Jauregui, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Alejandra Rodriguez-Romero, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Catalina Andrade-Vazquez and Alan De Leon-Yañez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) patients have a higher risk of developing left ventricular (LV) geometry abnormalities which can result in cardiac death. High titers of…
Abstract Number: 0440 • ACR Convergence 2021
Association Between Rheumatic Autoantibody Positivity and Immune-related Adverse Events
Kristen Mathias¹, Marco Lopez Velazquez¹ and Pankti Reid², ¹University of Chicago, Chicago, IL, ²University of Chicago Medical Center, Chicago, IL
Background/Purpose: The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy; however, their use can lead to off-target toxicities called immune-related adverse events (irAEs)…
Abstract Number: 0463 • ACR Convergence 2021
Treatment Persistence Among Medicare Beneficiaries with Seropositive Rheumatoid Arthritis Initiating Biologic or Targeted Synthetic DMARDs
Sang Hee Park¹, Taylor Schwartz², Xue Han¹, Scott Robinson², Sumie Kakehi¹, Keith Wittstock¹, Kris Norris², Anne Murunga², Alison Silverstein² and Jeffrey Sparks³, ¹Bristol Myers Squibb, Princeton, NJ, ²Avalere Health, Washington, DC, ³Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Recent exploratory clinical trial and retrospective studies1 suggest that patients with seropositive RA (rheumatoid factor [RF]+ and/or anti-cyclic citrullinated peptide [anti-CCP]+) treated with abatacept…
Abstract Number: 0568 • ACR Convergence 2021
Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD)
Amy Joseph¹, Jodi Yanagida¹, Xinliang Huang¹, Prabha Ranganathan¹, Melissa Laurie², Hong Xian¹ and Seth Eisen¹, ¹VA St. Louis Health Care System, St. Louis, MO, ²Bristol Myers Squibb, Princeton, NJ
Background/Purpose: The Department of Veterans Affairs (DVA) provides comprehensive medical care at minimal or no cost to 9 million veterans annually through 170 medical centers…
Abstract Number: 1230 • ACR Convergence 2021
Impact of Serologic Status on Clinical Responses to Upadacitinib or Abatacept in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Biologic DMARDs: Sub-Group Analysis from the Phase 3 SELECT-CHOICE Study
Andrea Rubbert-Roth¹, Jeffrey Sparks², Arnaud Constantin³, Ricardo Xavier⁴, Yanna Song⁵, Jessica Suboticki⁵ and Roy Fleischmann⁶, ¹Kantonspital St Gallen, St.Gallen, Switzerland, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³Toulouse University Hospital, Toulouse Cedex 9, France, ⁴Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁵AbbVie Inc., North Chicago, IL, ⁶University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In patients with RA who had a prior inadequate response or intolerance to biologic DMARDs, the oral Janus kinase inhibitor, upadacitinib (UPA), demonstrated superiority…
Abstract Number: 1517 • ACR Convergence 2021
Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade
Sophia Weinmann¹, Amanda Eudy² and David Pisetsky¹, ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: Patients with malignancy who develop rheumatic immune related adverse events (IRAEs) during immune checkpoint blockade (ICB) are commonly autoantibody negative. The change from chemotherapy…
Abstract Number: 1648 • ACR Convergence 2021
Increasing Rates of Positivity of Autoantibodies Indicates a Shorter Time-to-Diagnosis of Future Rheumatoid Arthritis
Dylan Bergstedt¹, Ryan Peterson², Marie Feser¹, LauraKay Moss¹, Geoffrey Thiele³, Ted Mikuls³, Jess Edison⁴, V. Michael Holers¹ and Kevin Deane⁵, ¹University of Colorado Denver, Aurora, CO, ²Colorado School of Public Health, Aurora, CO, ³University of Nebraska Medical Center, Omaha, NE, ⁴Walter Reed National Military Medical Center, Bethesda, MD, ⁵University of Colorado Denver, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations in autoantibodies to citrullinated protein antigens (ACPA) and rheumatoid factor (RF)…
Abstract Number: 1654 • ACR Convergence 2021
Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL
Azamat Satybaldyev, Galina Gridneva, Anna Misiyuk, Natalia Demidova, Kamalia Kasumova and Evgeny Nasonov, V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia
Background/Purpose: Comparison of frequency of different clinical features of the natural course at the stage of early rheumatoid arthritis (RA) in patients with young and…
Abstract Number: 0007 • ACR Convergence 2021
Divergent Reactivities of Rheumatoid Factors and Anti-Modified Protein Antibodies Converge on IgG Epitopes
Aisha Mergaert¹, Zihao Zheng¹, Michael Denny¹, Maya Amjadi¹, Janna Bashar¹, Michael Newton¹, Vivianne Malmström², Caroline Grönwall², Sara McCoy¹ and Miriam Shelef¹, ¹University of Wisconsin, Madison, WI, ²Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) patients often develop rheumatoid factors (RFs), antibodies that bind IgG Fc, and anti-modified protein antibodies (AMPAs), multi-reactive autoantibodies that commonly bind…
Abstract Number: 0015 • ACR Convergence 2021
Rheumatoid Factor Recognizes Specific Domains of IgG Heavy Chain Complexed with HLA Class II Molecules
Shanshan Zhang¹, Hideaki Tsuji¹, Hui Jin², Koji Kitagori¹, Shuji Akizuki³, Kosaku Murakami¹, Ran Nakashima¹, Hajime Yoshifuji¹, Masao Tanaka¹, Hisashi Arase², Koichiro Ohmura⁴ and Akio Morinobu¹, ¹Kyoto University, Kyoto, Japan, ²Osaka University, Osaka, Japan, ³Kyoto Universtiy, Kyoto City, Japan, ⁴Kobe City Medical Center General Hospital, Kobe, Japan
Background/Purpose: Rheumatoid factor (RF) is an autoantibody that binds to IgG Fc region (CH2 and CH3 domains) and is detectable in patients with rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].